CStone Receives the US FDA IND Clearance to Initiate P-II Trial of CS2009 in Advanced Solid Tumors

Shots:

• The US FDA has granted IND Clearance to initiate P-II trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) in pts with advanced solid tumors
• CS2009 is being evaluated in a P-II trial (currently enrolling) across Australia & China, spanning 15 cohorts to evaluate monotx. & combination regimens in 9 solid tumors, incl. NSCLC, colorectal cancer, TNBC, ES-SCLC, & Pt-resistant ovarian cancer
• Initial P-I data for CS2009, presented at the ESMO’25, showed a favorable safety profile & encouraging antitumor activity, with additional results from P-I & P-II studies expected at upcoming ASCO & ESMO congresses later this year

Ref: PRnewswire  | Image: CStone  | Press Release

Related News: CStone Pharmaceuticals’ Cejemly Receives the CHMP’s Positive Opinion for Treating NSCLC 

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com